Contraindicated in patients with a history of stroke or TIA. 90 mg twice daily (The recommended maintenance dose of ASA to be used with ticagrelor is 81 mg daily) 90 mg twice daily (The recommended maintenance dose of ASA to be used with ticagrelor is 81 mg daily) Duration Ideally up to 12 mo At least 12 mo for patients receiving DES Up to 12 mo for patients receiving BMS At least 12 mo for patients receiving DES Up to 12 mo for patients receiving BMS Ideally up to 12 mo At least 12 mo for patients receiving DES Up to 12 mo for patients receiving BMS Additional considerations Variability of response Greater than with prasugrel or ticagrelor. Factors impacting on response in some patients may include genetic predisposition to convert parent compound to active metabolite and drug interactions (eg, PPIs) Less than with clopidogrel. Impact of genotype and concomitant medications appears less than with clopidogrel. Less compared with clopidogrel. Impact of genotype and concomitant medications appears less than with clopidogrel. Platelet function testing Clinical utility not rigorously established. May be useful in selected patients with ischemic/thrombotic events while compliant with a clopidogrel regimen Clinical utility not rigorously established but less likely to be necessary given lesser degree of variation in response Clinical utility not rigorously established but less likely to be necessary given lesser degree of variation in response Genotyping Identifies patients with a diminished (CYP2C19 *2, *3 alleles) or enhanced (CYP2C17 allele) to form active metabolite. Role of genotyping in clinical management not rigorously established. 